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Time in Therapeutic Range, as a Determinant of All-Cause Mortality in
Patients With Hypertension
Michael Doumas, MD; Costas Tsioufis, MD; Ross Fletcher, MD; Richard Amdur, PhD; Charles Faselis, MD;
Vasilios Papademetriou, MD, DSc
Background-—Accumulating evidence indicates that reducing systolic blood pressure (BP) to <140 mm Hg improves health
outcomes; however, an optimal level has not yet been determined. Many population studies or post hoc analyses suggest a target
systolic BP between 120 and 140 mm Hg with increased risk above and below that range. We tested the hypothesis that
consistent control of systolic BP between 120 and 140 mm Hg—time in therapeutic range—is a strong determinant of all-cause
mortality among US veterans.
Methods and Results-—A total of 689 051 individuals from 15 Veterans Administration Medical Centers were followed over a
10-year period. Participants were classified as hypertensive, intermediate hypertensive, and normotensive according to the number
of elevated BP recordings (>3, 1 or 2, and none, respectively). Time within, above, or below therapeutic range (120–140 mm Hg)
was considered in quartiles and related to all-cause mortality. The study population consisted of 54% hypertensive, 19.9%
intermediate, and 26.1% normotensive participants; the corresponding mortality rates for the 3 groups were 11.5%, 8%, and 1.9%,
respectively (P<0.0001 for all comparisons). Mortality rates for hypertensive participants with BP consistently within, above, or
below the therapeutic range were 6.5%, 21.9%, and 33.1%, respectively (P<0.0001 for all comparisons). Mortality rates in
hypertensive participants increased from 6.5% in the most consistently controlled quartile (>75%) to 8.9%, 15.6%, and 23.5%
towards the less consistently controlled quartiles (50–75%, 25–50%, and <25%, respectively; P<0.0001 for all comparisons).
Conclusions-—An inverse and gradual association between time in therapeutic range and all-cause mortality was observed in this
large veteran cohort. Consistency of BP control over time is a strong determinant of all-cause mortality, and consistency of BP
control should be monitored in everyday clinical practice. ( J Am Heart Assoc. 2017;6:e007131. DOI: 10.1161/JAHA.117.
007131.)
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E levated blood pressure (BP) is a strong predictor ofcardiovascular risk and all-cause mortality. Since the
early landmark Veterans Administration (VA) studies demon-
strated impressive benefits from BP treatment and control,1,2
numerous randomized, prospectively controlled or compara-
tive trials, which included hundreds of thousands of patients,
demonstrated the benefits of treating hypertension.3–5 The
original VA studies targeted control of diastolic BP and
actually demonstrated benefit down to 100 mm Hg, or a
systolic BP between 140 and 150 mm Hg. Many other
studies confirmed these results, but later trials in isolated
systolic hypertension patients (Systolic Hypertension in the
Elderly Program) suggested that systolic BP is probably a
better target for treatment, particularly among middle aged or
older individuals.6 A limited number of studies addressed
different levels of diastolic BP to assess effects on outcomes
(Hypertension Optimal Treatment study), but results were
inconclusive because of small deltas in achieved BPs.7 Recent
meta-analyses suggested that there may be benefit from
reducing systolic BP between 130 and 140 mm Hg,8 but
others maintain that data are scarce in patients over the age
of 60 years,9 and guidelines even recently allow systolic BPs
up to 150 mm Hg in patients over the age of 60 years.9,10
Yet the recently published Systolic Pressure Intervention Trial
demonstrated beyond convincingly that reducing systolic BP
to the low 120s is much better than keeping it to the
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mid-130s.11 The study has been criticized, however, that it
used very stringent BP measurement methods, which are not
applicable to clinical practice.12,13 The fact is that existing
data suggest that the optimal BP reduction is somewhere
between 120 and 140 mm Hg systolic and the method of
measurement may have an influence on that optimal level.
It is clear that BP is not a stable measure, but rather it
is dynamic and can vary from minute to minute, day to
day, and from visit to visit even without drug regimen
modification. Blood pressure variability has been suggested
as an independent predictor of cardiovascular risk. So it
seems more practical and clinically relevant to define a
therapeutic range instead of a certain threshold as a
target of therapy.
We therefore hypothesized that a therapeutic range
between 120 and 140 mm Hg for SBP defines the optimal
therapeutic range for treatment and control of hypertension.
We introduced the term “time in therapeutic range” that
incorporates both the average BP value prevailing during long-
term follow-up and the degree of BP variability.
We hypothesized that patients with persistent BP within
the therapeutic range over time (75–100% of available BP
measurements) will have better outcomes than patients with
transient BP control or just the last BP within the therapeutic
range.
Patients and Methods
For the purpose of this study, we used longitudinal data
obtained from the US Veterans Affairs electronic medical
records. Acquisition, storage, and analysis of the data have
been previously described.14 In brief, the Department of
Veterans Affairs first deployed electronic data in 1982 as the
Decentralized Hospital Computer Program. The Computerized
Patient Record System was implemented systemwide in
1997. The system stores data longitudinally, it is searchable,
and allows individual medical centers to control the care of
the entire patient population. A vital-sign package that
included BP, pulse rate, respirations, weight, and height was
incorporated in the system in 1998 and data could be entered
directly into the database at the time of each visit. The ability
to assess BP control was enhanced in 2000 by combining the
databases housed at individual Veterans Administration
Medical Centers into a systemwide database, the Health
Data Repository. In recent years the VA Informatics and
Computing Infrastructure has been developed to host all data
available through the corporate data warehouse. Data from all
VA medical centers are available through a single server and
are accessible remotely. The system has been developed to
improve researchers’ access to VA data. The study was
approved by the institutional review board of the VA Medical
Center, Washington, DC. Since this was a retrospective
analysis, no informed consent was necessary.
Subjects
All patients receiving health care in 15 VA medical centers in
15 cities (Anchorage, AK; Baltimore, MD; Boston, MA;
Chicago, IL; Washington, DC; Fargo, ND; Honolulu, HI;
Houston, TX; Los Angeles, CA; Miami, FL; Minneapolis, MN;
New York, NY; Philadelphia, PA; Portland, OR; and San Juan,
PR), with BP readings in Computerized Patient Record System
were included. Blood pressure readings before September
2000 were only used to identify patients with hypertension,
whereas readings after September 2000 were used to assess
BP level and hypertension control rates. Individual patient
data files were de-identified and downloaded for analysis on a
PC running SAS (version 9.2, Cary, NC).
Blood Pressure Measurements
Blood pressure measurements were taken by trained health-
care professionals, who were instructed to follow standard
procedures for BP measurement: Patients were seated in a
Clinical Perspective
What Is New?
• We propose time in therapeutic range as a novel measure of
arterial hypertension management and provide verification
of its significance in a large cohort of US veterans.
• Patients with systolic blood pressure levels within the
therapeutic range (120–140 mm Hg) had significantly lower
mortality rates than patients with blood pressure levels
above or below this range, while the time in therapeutic
range was a strong survival predictor: patients with
consistent (>50%) compared with patients with inconsistent
(<50%) blood pressure values within this range had 2- to 3-
fold lower mortality rates.
What Are the Clinical Implications?
• The substantial survival benefits of consistent blood pres-
sure control over time draw attention to the long-term
follow-up of patients with arterial hypertension: physicians
managing patients with arterial hypertension (cardiologists,
nephrologists, internists, primary care) should aim not only
to lower blood pressure levels but also to make every
possible effort to maintain blood pressure within the
therapeutic range of 120 and 140 mm Hg most of the time
during the lifelong follow-up of the patients, since blood
pressure levels above or below this range or inconsistent
blood pressure control are associated with significantly
increased mortality rates.
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comfortable position with the back supported, legs uncrossed,
and BP taken after 3 to 5 minutes of rest. BP was taken at
least twice and entered into the vital-sign package. In some
centers it was mandated that BP be rechecked by the
attending physician if found elevated by the clinic nurse.
Standard cuffs were used in most patients, but large cuffs
were available for patients with large arm circumference. All
BP readings, age, race, sex, height, and weight were recorded.
Records were reviewed anonymously. An elevated BP reading
was defined as a systolic BP >140 or diastolic >90. Patients
were identified as hypertensive after 3 elevated BP readings
were documented at 3 separate visits. Normotensive patients
were defined as those patients with at least 3 days of BP
readings, but no days with BP elevated. Patients with 3 or
more readings, but only 1 or 2 days with elevated BPs were
classified as intermediate (intermediate hypertension) and
patients with fewer than 3 readings were excluded from this
analysis. For patients with hypertension, the follow-up period
started after the third elevated BP was recorded. Age at entry
into the data set was used (ie, on the first day with BP [for
normotensives], or on the date of the third elevated reading
[for patients with hypertension]).
Data Analysis
BP readings were dropped if any of the following was true:
missing systolic or diastolic, systolic < diastolic, systolic
>300, systolic <60, diastolic <30, or diastolic >180. For each
visit, patients were considered to be normotensive if systolic
<140 and diastolic <90. For patients with multiple visits in the
same month, the last reading of the month was used to
represent that calendar month. Months with no readings for a
given patient were not imputed for that patient. The
percentage of patients who were normotensive for each
month was calculated, based on all patients with readings for
that month. The yearly percentage of patients with normalized
BP was calculated based on the last BP of each calendar year.
Yearly change in percentage normotensive was calculated for
the period from September 2000 to August 2012. Monthly
and yearly change in average BP values for the population
were also calculated based on the average BP value for each
month and the last available value for each calendar year. Age
was defined at the time of the first BP reading for those with
normal BP and at the time of the first BP after being identified
as hypertensive (ie, the first reading after the third elevated
reading for patients with hypertension).
Classification Based on BP Values
Participants were classified as never-hypertensive (normoten-
sives) if none of the recorded BP values was >140/
90 mm Hg. Participants were classified as having
“intermediate hypertension” if only 1 or 2 elevated BPs were
recorded. Participants were classified as hypertensive if 3 or
more elevated BPs were recorded.
Blood Pressure Control and All-Cause Mortality
All-cause mortality was assessed for each 10-mm Hg decre-
ments for the 12 years of follow-up from 2000 to 2012. The
last recorded BP was considered or the last before death.
Time in Therapeutic Range
Based on early observations, we introduced the term “time in
therapeutic range” (TTR), which expresses the percentage of
BP measurements recorded within a certain window (TTR for
BP window 120–140 mm Hg). TTR represents the average of
all BP measurements recorded during the follow-up period for
each patient that fall within the window and the percentage in
TTR represents the degree of BP variability for that patient.
Thus, TTR reflects the prevailing BP during the follow-up
period and the magnitude of BP variability.
Statistical Analysis
Categorical data were expressed as counts and percentages
and continuous data were expressed as either means and SDs
or medians and interquartile ranges. Means were compared
using Student t test, counts and proportions were compared
using the v2 test or the Fisher exact test, and medians were
compared using the Wilcoxon rank-sum test. Hazard ratios
were calculated using Cox regression models adjusted for city
location, age, sex, and race. The proportional-hazards
assumption was assessed by testing for the interaction of
time with treatment group.
Multivariable modeling techniques were used in order to
examine whether patient age, sex, race, city, and time in
treatment had independent effects on mortality. Multiple
regression (using a general linear model as implemented in
the GLM procedure in SAS) was used to examine prediction
models for percent of months controlled during the last
calendar year available for each subject. Predictors included
age group (<55, 55–75, and >75 years), sex, race, city, and
number of months in the data set after being identified as
hypertensive. Adjusted final percent elevated, the percent of
months elevated in the final year, adjusted for the other
covariates, was obtained using the ls means option in the SAS
GLM procedure. In large data sets, changes over time can
occur because of different patients being in the cohort at
different time points. In order to determine the significance of
within-subject changes over time, fixed-effects mixed models
were used, with the SAS GLM procedures, using the “absorb”
option. This type of model only examines subjects who vary
DOI: 10.1161/JAHA.117.007131 Journal of the American Heart Association 3























on the outcome over time, using each subject as their own
control. P values <0.05 were considered significant. Data
analysis was performed by 1 of the authors (R.A.) using SAS
(version 9.2, Cary, NC).
Results
Baseline Characteristics
The current study included 689 051 patients from 15 Veterans
Affairs Medical Centers in a wide range of geographic
distributions. Of those, 371 996 (54%) met the criteria of
established hypertension (at least 3 elevated BPs during the
follow-up period), 137 370 (19.9%) were normotensives (had
no elevated BPs, never-hypertensive), while 179 685 (26.1%)
met the criteria for intermediate hypertension (MID-hyperten-
sion, had 1 or 2 elevated BPs). The main baseline character-
istics of study participants are shown in Table 1. The age of
patients with established hypertension at the time of diagnosis
(third elevated BP measurement) was 62.413.3 years and
the vast majority (95.9%) of them were male. Of the total
hypertensive population, 157 522 (41.4%) patients declared
ethnicity, whereas 214 474 patients (58.6%) did not. Of those
who declared ethnicity, 26% were black, 22% were Hispanic,
50.3% were whites, and 1.7% Asian-other. Similar patterns of
distribution of ethnicity and nondeclared ethnicity were noted
also in the other 2 groups, MID-hypertensives and never-
hypertensives (Table 1). Patients with hypertension were older
compared with participants in the intermediate and the
normotensive groups. The number of BP readings was 4 times
higher in patients with hypertension as compared with
participants in the other 2 groups.
Mortality by Last Recorded BP
All-cause mortality according to the last systolic BP reading
was significantly higher in patients with established hyperten-
sion compared with patients in the intermediate and the
normotensive groups. This was evident for each 10-mm Hg
increment of systolic BP between 100 and 120 mm Hg, 120 to
140 mm Hg, and >140 mm Hg (Figure 1A through 1C). The
lowest mortality rate in patients with established hypertension
(Figure 1A) was seen in the group of patients who achieved
systolic BP between 130 and 140 mm Hg (11%), and in
patients with MID-hypertension (Figure 1B) in patients with
achieved BP between 120 and 130 mm Hg systolic (7.5%).
Among normotensive patients (Figure 1C), the lowest mortal-
ity rate was also seen in individuals with systolic BP between
120 and 130 mm Hg (1.5%), but differences were small above
and below that range. Overall, the lowest mortality rate was
noted between 130 and 140 mm Hg among patients with
hypertension and between 120 and 130 mm Hg among
patients with MID–hypertension or normotensive individuals
(Figure S1A). When considering 20-mm Hg increments, mor-
tality rates based on achieved systolic BP between 120 and
140 mm Hg were 11.5%, 8%, and 1.9% among patients with
hypertension, MID-hypertensive, and normotensive, respec-
tively (Figure S1B). Total mortality rates unveiled a U-shaped
pattern when the last systolic BP reading was taken into
account. Given the uncertainty about the optimal range of
achieved or last systolic BPs (130–140 mm Hg in hyperten-
sives, but 120–130 mm Hg in MID–hypertensives), we con-
sidered a broader range of prevailing BPs (120–140 mm Hg)
as a therapeutic target to test our hypothesis that TTR is a
strong determinant of all-cause mortality.
Table 1. Baseline Characteristics of Study Participants
Variable
Patient Type
TotalHTN (n=371 996) MID (n=179 685) NORM (n=137 370)
Race
Black 40 997 (26%) 8216 (19.4%) 4920 (19.9%) 54 133
Hispanic 34 660 (22%) 8556 (20.25%) 5817 (23.5%) 49 033
White 79 184 (50.3%) 24 713 (58.4%) 13 596 (54.9%) 117 493
Asian, other 2681 (1.7%) 813 (1.9%) 418 (1.6%) 3912
Ethnicity not declared 214 474 (58.6%) 137 387 (76.5%) 112 619 (82.2%) 464 480
Sex
Female 14 961 (38.3%) 10 042 (25.7%) 14 059 (36.0%) 39 062
Male 357 020 (54.9%) 169 631 (26.1%) 123 300 (19.0%) 649 913
Age, y 62.413.3 57.816.2 51.817.7
Number of BP readings 31.925.9 8.16.1 6.64.8
Number of elevated BP readings 11.114.2 1.40.5 00
BP indicates blood pressure; HTN, hypertension; MID, intermediate; NORM, normal.
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Mortality Rates by Time in Therapeutic Range
In order to test our second hypothesis, we compared all-
cause mortality rates according to the consistency of BP
values within the therapeutic range over time in 4 groups: BP
control most of the time (>75%), more than half of the time
(50–75%), less than half of the time (25–50%), and only
occasionally (<25%). In patients with established hyperten-
sion, the average number of BP measurements during the
10 years of follow-up was 31.9/patient. A gradual, inverse,
and strong association between mortality rates and consis-
tency of systolic BP control was observed (Figure 2A).
All-cause mortality rates were increased gradually from
6.54% in the most consistently controlled group (>75% of
BP readings over-the-time within the optimal therapeutic
range), to 8.87%, 15.62%, and 23.52% moving towards the
less consistently controlled groups (50–75%, 25–50%, and
<25%, respectively, P<0.0001).
Similar patterns were noted in participants with MID
hypertension (Figure 2B), but not among normotensive par-
ticipants (Figure 2C). We also compared mortality rates of
patients with BPs most of the time (>75%) within the
therapeutic range to those with BPs most of the time above
or below the therapeutic range (Figure S2). Mortality rates
were much lower for patients with BPs mostly within
Figure 1. A, Death rates by last systolic BP in patients with established hypertension (>3 elevated BPs). B, Death rates by last systolic BP in
patients with only 2 elevated systolic BPs (MID-hypertensive group). C, Death rates by last systolic BP in nonhypertensives. D, Mortality rates by
last systolic BP between 120 and 140 mmHg for Normal, Mid HTN, Hypertension, by 10 mmHg increments. E, Mortality rates by last systolic BP
between 120 and 140 mmHg for Normal, Mid HTN, Hypertension, by 20mmHg increments. BP indicates blood pressure; HTN, hypertension;
SBP, systolic blood pressure.
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therapeutic range (6.5%) as compared with those above
(21.9%) or below the therapeutic range (33.1%) (P<0.0001;
Figure S2). The survival benefits of patients with systolic BP
levels within the optimal therapeutic range most of the time
compared with patients with systolic BP levels over and under
this therapeutic range were independent of age and evident
for all age groups (<55, 55–75, and >75 years) (Figure S3).
All-cause mortality rates in younger hypertensive patients
(<55 years of age) were 2.9%, 11.2%, and 20.1% in patients
with systolic BP levels most of the time within, over, and
under the therapeutic range, respectively. All-cause mortality
rates in older patients (55–75 years) were 6.7%, 19.3%, and
32.5% in the 3 groups, respectively, while in the very old
hypertensive participants (>75 years) the respective all-cause
mortality rates were 20.8%, 33.6%, and 57.7%.
Multivariate logistic regression analysis (adjusted for age,
sex, race, and ethnicity) revealed that compared with the
most consistently controlled group (systolic BP values within
the therapeutic range >75% of the time) as the reference
group, the odds ratios for all-cause mortality in hypertensive
patients (Table 2) were 1.14% (95% confidence interval, 1.07–
1.21) for the second group (50–75% of the time), 1.92% (95%
confidence interval, 1.81–2.04) for the third group (25–50% of
the time), and 2.97 (95% confidence interval, 2.80–3.16) for
the less consistently controlled group (<25% of the time).
Similar trends were noted for MID-hypertensive patients but
not in normotensive participants. In addition, the respective
mortality rates and odds ratios for systolic BP values above
and below the therapeutic range according to consistency
over-the-time in hypertensive patients are provided in
Table S1.
Cox regression estimates for survival based on the time in
therapeutic range in the 4 categories are depicted in Table 3
and Figure 3. Table 3 demonstrates increased mortality risk
with less consistency in BP control, but the difference
between 50% to 75% and 75% to 100% TTR was small, so in
essence TTR >50% provides close to optimal results. Figure 3
shows that the separation of lines between more and less
consistently controlled patients occurs early during the first
year of the follow-up period and increases over time during
% BP readings in Therapeutic Range
% BP readings in Therapeutic Range
Figure 2. A, Mortality rates among patients with established hypertension based on percent of readings in therapeutic range. B, Mortality
rates among patients with MID-hypertension based on percent of readings in therapeutic range. C, Mortality rates among never-hypertensive
patients based on percent of readings in therapeutic range. BP indicates blood pressure.
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follow-up. Again, the survival benefit of the 2 groups with the
most consistent BP control over-the-time is quite similar,
suggesting that systolic BP needs to be within the optimal
therapeutic range at least half of the time in order to attain
the best long-term survival benefits.
Discussion
This large, longitudinal study of US veterans has 2 main
findings. First, systolic BP levels within the proposed optimal
therapeutic range (120–140 mm Hg) are associated with
significantly lower all-cause mortality rates compared with BP
levels over or under this therapeutic range in patients with
hypertension. Second, all-cause mortality strongly depends on
the consistency of BP control over time. Total mortality rates
were significantly lower among hypertensive patients, with
most BP measurements remaining within the therapeutic
(>75%) compared with occasional BP control (<25% of the
time). Therefore, the study findings support our hypothesis
that in patients with established hypertension, best outcomes
are obtainable with stricter hypertension control and more
time in a defined therapeutic range. Survival is significantly
lower when systolic BP levels are maintained between 120
and 140 mm Hg most of the time in this hypertensive
population. In fact, in patients with systolic BP measurements
in therapeutic range (120–140 mm Hg) >75% of the time,
mortality was about half of what was seen in the same
population achieving last BP in the same range (6.5% versus
11.5%).
These findings are of major clinical importance for the
optimal management of patients with arterial hypertension in
real-life clinical practice. Similar findings were found for the
group of patients in the MID-hypertension group. These
patients were identified as such if they only had 1 or 2
elevated BPs recorded over the follow-up period. It is likely
that most of these patients were indeed hypertensive, but
were either well treated and controlled or their third elevated
BP was not recorded because of infrequent visits (on average
they only had 8.1 BP measurements, of which only 1.4 were
elevated). Mortality rates in this intermediate group of
Table 2. Logistic Regression Odds Ratios, Number of Deaths, and % Mortality by TTR for Patients With Established Hypertension
and MID-HTN
Level N Died %Dead OR (95% CI) P Value
Established HTN
TTR 0% to 25% 74 781 17 585 22.9 2.97 (2.80–3.16) <0.0001
>25% to 50% 147 747 23 081 15.6 1.92 (1.81–2.04) <0.0001
>50% to 75% 129 226 11 463 8.8 1.14 (1.07–1.21) <0.0001
>75% to 100% 20 242 1323 6.5 Reference group
MID-HTN
TTR 0% to 25% 15 918 2717 17.1 2.67 (2.49–2.86) <0.0001
>25% to 50% 56 200 7038 12.5 1.91 (1.80–2.03) <0.0001
>50% to 75% 77 600 6839 8.8 1.39 (1.31–1.47) <0.0001
>75% to 100% 29 962 1671 5.6 Reference group
Multivariate regression analysis, controlling for city, age, sex, and race. CI indicates confidence interval; HTN, hypertension; MID, intermediate; OR, odds ratio; TTR, time in therapeutic
range.
Table 3. Cox Regression Models Examined Associations Between Mortality and the Proportion of TTR, Using 3 Categorical
Variables Where 76% to 100% was the Referent Group
Parameter Parameter Estimate (SE) v2 P Value HR (95% CI)
TTR
0% to 25% 0.78 (0.03) 657.22 <0.0001 2.18 (2.06–2.32)
26% to 50% 0.37 (0.03) 148.05 <0.0001 1.45 (1.36–1.53)
51% to 75% 0.07 (0.03) 5.23 0.022 0.93 (0.88–0.99)
76% to 100% Reference grp.
Cox models adjusted for city location, age, race, and sex. CI indicates confidence interval; HR, hazard ratio; TTR, time in therapeutic range.
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patients assessed by last BP in the range of 120 and
140 mm Hg was about 8% as compared with 11.5% for
patients with established hypertension (Figure 1A and 1B). Of
interest is that this group of patients also followed the same
pattern of J-shape curve. Patients with no elevated BPs during
the follow-up period (Never–Hypertensive) had much lower
mortality rates. This group of patients was truncated since
BPs >140 mm Hg were excluded by definition and patients
with systolic BPs <100 mm Hg were excluded because of
comorbidities. Nevertheless, the optimal systolic BP (last) was
between 120 and 140 mm Hg.
The concept of the optimal therapeutic range between 120
and 140 mm Hg for systolic BP in hypertensive patients was
based on a wealth of data. Accumulating evidence from large,
randomized, controlled studies demonstrated without any
doubt the benefits of treating elevated BP below 140 mm Hg,
and this recommendation has been adopted by all current
guidelines for the management of arterial hyperten-
sion.10,15,16 Observational studies have established the
dogma “the lower, the better” in the hypertension field, since
cardiovascular events (myocardial infarction and stroke) were
significantly fewer with lower BP values down to
110 mm Hg.17 However, a J-curve association between BP
values and outcomes has been observed in some prospective
studies, and in most retrospective analyses, especially in
patients with coronary artery disease,18–21 raising doubts
about aggressive BP reduction. Although the J-curve concept
fell out of favor for more than a decade, mainly because of the
findings of the Hypertension Optimal Treatment study,7 a post
hoc analysis of the INVEST (International Verapamil SR/
Trandolapril) study (later reinforced by several other studies)
rekindled the concerns about lowering BP very aggressively.22
The turning point of cardiovascular benefits to risks with
systolic BP reduction was at 119 mm Hg in the INVEST study.
These data generated the hypothesis of the optimal thera-
peutic range between 120 and 140 mm Hg for systolic BP in
hypertensive patients. A therapeutic range rather than a fixed
target is preferable and more suitable for clinical practice,
since BP level varies from day to day and from visit to visit
even without interventions.
We opted to focus on systolic BP alone, instead of diastolic
BP or both for several reasons. Although the original VA
studies and the first versions of Joint National Committee
guidelines have focused on diastolic BP alone, it was later
realized that systolic BP is a stronger determinant of
cardiovascular outcomes in hypertensive patients, especially
in older age.23–25 Indeed, the management of study partic-
ipants in the recent Systolic Pressure Intervention Trial was
based on systolic BP levels alone, almost ignoring diastolic BP
levels.11
The TTR is an innovative concept in the field of
hypertension. Guidelines for the management of main
cardiovascular risk factors (arterial hypertension, diabetes
mellitus, and dyslipidemia) have adopted a cut-off level
approach, defining a threshold level to be achieved, which in
the case of arterial hypertension is a BP level <140/
90 mm Hg. However, no recommendation or guidance is
given to practicing physicians on what to do once BP levels
are below that threshold. Is any level of BP below the
therapeutic threshold acceptable? Is 138 similarly accept-
able to 132, 124, and 115 mm Hg? What are we supposed
to do with the risk of too low level of BP? In other fields of
cardiovascular medicine, such as in anticoagulant therapy
with vitamin-K antagonists, a therapeutic range (window)
instead of a certain threshold has been established. The
adoption of a range is mainly based on the detrimental
effects of hypo- and hypertherapy outside the therapeutic
range. In the case of anticoagulation, a major increase in
risk of complications has been established above and below
the therapeutic range (international normalized ratio 2.0–
3.0). Real-life practice indicates that BP varies significantly
over time, just like international normalized ratio levels with
vitamin-K antagonists, so it seems more practical and
clinically meaningful to define a therapeutic range instead
of a certain threshold for BP control, and take into account
the TTR. TTR of BP control, as in the case of vitamin-K
antagonists,26 is strongly related to outcomes. Consistency
of BP control over time is of sentinel importance in the
management of arterial hypertension, since BP levels vary
significantly during the lifelong antihypertensive therapy in
the majority of patients. Consistency of BP control defines
the real BP load over time, and is expected to provide a
more accurate estimate of future cardiovascular events than
a BP value at any specific time-point. Consistency of BP
control over time might be expressed as the percentage of
BP control measurements over time.
Figure 3. Cox regression models: mortality rates for patients
with systolic BP measurements in therapeutic range 0% to 25%,
25% to 50%, 50% to 75%, or >75% of BP measurements. Follow-up
to 120 mo. Corrected for location, age, sex, and race. BP
indicates blood pressure; SBP, systolic blood pressure.
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The J-curve controversy is based on the achieved BP levels
(ie, the last BP reading of participants in randomized trials).
Although the last or achieved BP provides very important
information and consistently reflects the J-shape curve
phenomenon (observed in our study as well, Figure 1), it
has limitations; it is affected by reverse causality and it is
contaminated by confounders (ie, last BP may reflect heart
failure that developed in the past few months, cancer or
weight loss, etc that happened in the last few months of
follow-up or before death). It does not necessarily reflect the
hypertensive load over time or over a lifetime. On the other
hand, TTR reflects both the variability and hypertension
burden over time. Blood pressure variability during lifelong
antihypertensive therapy needs to be taken into account.
Long-term BP variability has been associated with cardiovas-
cular outcomes in post hoc analyses of several large
trials.27,28 Although long-term BP variability may contribute
to cardiovascular risk, it has not by itself become a
therapeutic target yet. We believe the average prevailing BP
over time and the degree of variability (intrinsic or because of
non–drug compliance or medication change) are major
determinants of cardiovascular outcomes. The lower the
average over time BP (within the therapeutic window) and the
higher percentage TTR, the lower the risk for premature death.
Thus, TTR for BP control may be a useful measure for everyday
clinical practice. This is the first time we (or anyone) used the
concept of TTR as a determinant of mortality in patients with
hypertension. In our study population, systolic BP values
within the therapeutic range most of the time (>75%) were
associated with the lowest all-cause mortality when compared
with transient (25–50%) or occasional (<25%) BP values within
the optimal therapeutic range. The survival benefits were
evident even in the group of patients with systolic BP values
within the therapeutic range more than half of the time (50–
75%), rendering our study findings more applicable in real-life
clinical practice. It can be rationally assumed that BP values
between 120 and 140 mm Hg can be achieved more easily in
60% instead of 90% of the measurements during lifelong
antihypertensive therapy.
Of note, the mortality rates were significantly higher in
hypertensive patients who had BP values over or under the
optimal therapeutic range most of the time rather than
occasionally (>75% versus <25%, respectively) (9.63% versus
21.87%; P<0.0001 for values over the therapeutic range; and
13.93% versus 33.08%; P<0.0001 for values under the thera-
peutic range), indicating that BP values outside the therapeutic
range are more detrimental when they are consistently outside
the therapeutic range. Thus, being hypertensive or hypotensive
most of the time is more deleterious than having occasional
measures outside the range.
Two more findings in our study are noteworthy and merit
discussion: the mortality rate of individuals in the
intermediate BP group and the mortality rates in normoten-
sive individuals.
The mortality rates of individuals classified in the interme-
diate BP group (1 or 2 elevated BP readings during the study
period) was lower than the ones of hypertensive patients (as
expected) but significantly higher than the mortality rates of
normotensive individuals. This can be translated as an
exaggerated mortality risk in individuals with only 1 or 2
cases of documented BP elevations over time compared with
individuals who were normotensives all the time. To our
knowledge, this is a unique finding, and this group of
individuals has never been tested before. Although these
individuals cannot be characterized as hypertensives by
currently used diagnostic criteria, they are at significantly
increased risk of dying compared with “all-time” normotensive
subjects. This group of individuals is currently included in
normotension and has to be better characterized and
assessed in future studies.
In normotensive individuals, the mortality rates with BP
values within the therapeutic range most of the time were
not significantly different than the ones of normotensives
with BP values <120 mm Hg most of the time. Of note, BP
values <120 mm Hg in reality mean 100 to 120 mm Hg
since patients with any measure of BP <100 mm Hg were
excluded from the study. This observation can be inter-
preted in different ways. On the one hand, BP values
consistently below 120 mm Hg are not detrimental in
normotensive individuals, unlike hypertensive patients. This
is in line with observational data from other studies
reporting better outcomes with lower BP values in
normotensive individuals. On the other hand, BP values
consistently within the prehypertension range are not
associated with increased total mortality when compared
with BP values consistently below 120 mm Hg. This finding
is in line with 3 large meta-analyses that did not find any
association between prehypertension and all-cause mortal-
ity.29–31 Since prehypertension in our study was based on
multiple BP readings over-the-time (7 in average), this
finding is further credited and adds more fuel on question-
ing the necessity and utility of the term prehypertension, a
classification currently used for patients with BP values
between 120 and 140 mm Hg.
Our study has several strengths and limitations. Its major
strength is to propose the TTR as an alternative approach for
the follow-up of hypertensive patients and assess this concept
in a very large database of almost 700 000 individuals from
15 different US states, with almost 15 million BP readings
during a multiyear study period. The study is mainly limited by
the lack of specific information of some baseline character-
istics (body mass index, concomitant disease, medications,
and glycemic, lipid, and renal status). Missing information
would be important for adjustments and subgroup analyses;
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however, it is not likely to significantly alter our study findings.
The study is also limited by the very small number of female
participants, narrowing the generalization of study findings to
male individuals alone. Finally, information about cardiovas-
cular morbidity and mortality is not available; however, all-
cause mortality is the hardest end point, and the only one that
cannot be debated at all.
Conclusions
From analysis of these data we can therefore conclude the
following:
1. In patients with established hypertension or milder-
intermediate hypertension (1, 2 BP elevations during
follow-up), consistent control of systolic BP in the range
of 120 to 140 mm Hg provides the lowest risk for all-
cause mortality.
2. In these 2 groups of patients, persistent systolic BP
>140 mm Hg or between 100 and 120 mm Hg is asso-
ciated with higher mortality risk.
3. In never-hypertensive patients, risk of death from all
causes was similar, with systolic BPs 100 to 120 or 120 to
140 mm Hg.
4. TTR is a useful index of risk over time in patients
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Table S1. Logistic regression odds ratios, number of deaths and % mortality by time in therapeutic range 
(TTR) patients with established hypertension (three or more elevated BPs, N=371,996). Multivariate 




Level N Died %dead OR(95% CI) P 
In therapeutic 
range 
0-25% 74781 17585 22.9 2.97 (2.80 – 
3.16) 
<.0001 
 >25-50% 147747 23081 15.6 1.92 (1.81 – 
2.04) 
<.0001 
 >50-75% 129226 11463 8.8 1.14 (1.07 – 
1.21) 
<.0001 
 >75-100% 20242 1323 6.5 Reference 
group 
 
       
Over Therapeutic 
Range 
0-25% 91072 8774 9.6 .53 (.51 - .55) <.0001 
 >25-50% 137612 17547 12.7 .59 (.58 - .61) <.0001 
 >50-75% 91634 15830 17.2 .78 (.75 - .80) <.0001 
 >75-100% 51678 11301 21.8 Reference 
group 
 




0-25% 328397 45755 13.9 .25 (.20 - .30) <.0001 
 >25-50% 39080 6602 16.9 .36 (.29 - .44) <.0001 
 >50-75% 3993 921 23.1 .61 (.49 - .76) <.0001 
















Figure S1. A. Mortality rates by last systolic BP between 120 and 140 mmHg for Normal, Mid HTN, 
Hypertension. B. Mortality rates by last systolic BP between 120 and 140 mmHg for Normal, Mid HTN, 














Figure S2. Mortality rates in patients with established hypertension being >75% of time (% readings) 
within, over, or under the therapeutic range (120-140 mmHg). TR: therapeutic range. 
 























Figure S3. Mortality rates in patients being >75% of time (%readings) within, over or under the 
therapeutic range (120-140 mmHg) by age group. BP: blood pressure.  
BP Pattern 
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